ArticleScientific reports2025
Uncovering potent natural phytochemicals targeting SARS-COV-2 spike protein variants: molecular dynamics insights.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 remains a critical global health concern due to its high transmissibility, evolving variants, and the absence of a universally effective treatment. Phytocompounds, known for their antiviral, anti-inflammatory, and immunomodulatory properties, continue to be explored as potential therapeutic agents. This study evaluated 20 phytocompounds and four approved antiviral drugs, Remdesivir, Favipiravir, Hydroxychloroquine, and Ivermectin, against nine SARS-CoV-2 spike glycoprotein structures, including five wild-type and four variants (Alpha, Beta, Delta, and Omicron). Molecular docking using two software platforms identified ursolic acid, betulinic acid, β-sitosterol, and ivermectin as top candidates, with binding affinities ranging from - 6.7 to - 9.6 kcal/mol. These compounds also displayed favorable pharmacokinetic properties and druggability. 100 ns molecular dynamics simulations were performed on the highest-affinity complexes to assess stability. Betulinic acid and β-sitosterol demonstrated stable binding interactions, with low RMSD values (~ 0.2-0.3 nm) and consistent hydrogen bonding (1-3 bonds), suggesting structural stability. In contrast, ursolic acid and ivermectin showed unstable binding and higher structural fluctuations during simulation. Overall, the study highlights betulinic acid and β-sitosterol as presumptive SARS-CoV-2 inhibitors, warranting further experimental validation through in vitro and in vivo studies to confirm their therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.